Advanced Search

 

Study ID Status Title Patient Level Data
SUM30014 Completed A double-blind, placebo-controlled, parallel-group study to evaluate two dose levels of sumatriptan suppository (12.5mg and 25mg) in the acute treatment of migraine attack, with an optional repeat dose for headache recurrence.
SUM30015 Completed A double-blind, placebo-controlled cross-over study to evaluate the acute effects of subcutaneous GR43175C (6mg) in cluster headache.
SUM30017 Completed A double-blind study to compare oral GR43175C (100mg) with oral aspirin (900mg) and metoclopramide (10mg) in the acute treatment of migraine.
SUM30018 Completed A double-blind study to compare oral GR43175C with oral Cafergot (ergotamine + caffeine) in the acute treatment of migraine.
SUM30019 Completed The acute treatment of migraine with oral GR43175C: a placebo-controlled dose comparison, multicentre, multinational study.
SUM30020 Completed Multi-center evaluation of the safety and efficacy of subcutaneous GR43175C in patients with acute migraine attacks – using a two-dose regimen.
SUM30021 Completed Multi-center evaluation of the safety and efficacy of subcutaneous GR43175C in patients with acute migraine attacks – using a two-dose regimen.
SUM30023 Completed A double-blind study to compare the efficacy of subcutaneous GR43175C with that of subcutaneous placebo injection in the acute treatment of migraine.
SUM30024 Completed Multicenter evaluation of the safety and efficacy of subcutaneous GR43175C in patients with acute migraine attacks.
SUM30026 Completed The acute treatment of migraine with subcutaneous GR43175C. A placebo-controlled, dose-comparison, multicentre, multinational study.
SUM30026_1 Completed Open, additional treatment with GR43175C by subcutaneous injection for patients participating in protocol S2BT02.
SUM30027 Completed A randomized, double-blind, placebo-controlled study to evaluate headache pain relief with sumatriptan nasal spray (5mg, 10mg, and 20mg) across three migraine attacks.
SUM30028 Completed A double-blind, placebo-controlled, parallel group study to evaluate two dose levels (10mg and 20mg) of intranasal sumatriptan in the acute treatment of migraine attack.
SUM30029 Completed An open design study to evaluate the efficacy and tolerability of sumatriptan nasal spray (20mg + optional 20mg dose for headache recurrence) in the acute treatment of migraine during a 12 month period.
SUM30030 Completed A randomised, double-blind, double-dummy, cross-over study to compare the efficacy and safety of sumatriptan nasal spray (20mg) with dihydroergotamine (DHE) nasal spray (1mg plus optional 1mg) in the acute treatment of migraine.
SUM30031 Completed A Randomized Double-Blind, Placebo-Controlled, Crossover Protocol to Evaluate the Safety and Efficacy of 12.5mg and 25mg Sumatriptan Suppository in the Treatment of Multiple Migraine Attacks.
SUM30032 Completed A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of Sumatriptan Suppositories in the Acute Treatment of Three Migraine Attacks.
SUM30034 Completed A double-blind, placebo-controlled study to compare the efficacy and safety of oral sumatriptan (25mg, 50mg and 100mg film-coated tablets) in the acute treatment of migraine with an optional second dose to treat recurrence.
SUM30035 Completed A double-blind, crossover study to assess patient preference, efficacy and safety of oral sumatriptan (25mg, 50mg and 100mg film-coated tablets) in the acute treatment of migraine.
SUM30037 Completed A double-blind placebo controlled study to assess the efficacy/safety of oral sumatriptan (50mg film coated tablet) in the acute treatment of migraine with an optional second dose to treat recurrence.
SUM30042 Completed A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Cross-Over Study to Investigate the Efficacy, Safety and Tolerability of Sumatriptan Nasal Spray (10mg or 20mg) in the Treatment of Acute Migraine in Patients Aged 12-17.
SUM30045 Completed A Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate Two Dose Levels (5mg And 20mg) Of Sumatriptan Nasal Spray In The Acute Treatment Of A Single Migraine Attack In Adolescent Migraineurs (12-17 Years Of Age) Study Listed on ClinicalStudyDataRequest.com
SUM30046 Completed A randomised, double-blind, single-attack, placebo-controlled, parallel group evaluation of the efficacy and tolerability of sumatriptan Fast Disintegrating Tablets (FDT) 50 mg and 100 mg versus placebo during the mild pain phase of a migraine attack. Study Listed on ClinicalStudyDataRequest.com
SUM30047 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Attack Study to Evaluate the Onset of Efficacy of a New Formulation of Sumatriptan Tablets 50mg and 100mg in the Acute Treatment of Migraine Study Listed on ClinicalStudyDataRequest.com
SUM30053 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Attack Study to Evaluate the Onset of Efficacy of a New Formulation of Sumatriptan Tablets 50mg and 100mg in the Acute Treatment of Migraine (EU study). Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.